1 Min Read
March 31 (Reuters) - GlaxoSmithKline:
* GSK starts phase III study with Mepolizumab in patients with severe Hypereosinophilic syndrome Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.